Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Octreotide Acetate

FDA-approved product (injectable, injection), marketed as Bynfezia Pen, Mycapssa, Octreotide Acetate and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Octreotide Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Carcinoid tumor
  • Metastasis
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Somatostatin and analogues
FDA pharmacologic class
Somatostatin Analog FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Octreotide Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Octreotide Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

    NCT00005906 · start 2000-06

    Registered record
    Registry ID
    NCT00005906
    Conditions
    Lymphangioleiomyomatosis; Lymphangiomyomas; Pleural Effusions; Ascites
    Interventions
    Octreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    Not recorded
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphangioleiomyomatosis; Lymphangiomyomas; Pleural Effusions; Ascites
    InterventionOctreotide
    PhasePhase 2
    Registry statusCompleted

  • New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

    NCT00001849 · start 1999-05-20

    Registered record
    Registry ID
    NCT00001849
    Conditions
    Cushing Syndrome; Endocrine Disease
    Interventions
    Pentetreotide; 18F-DOPA; CT scan; MRI; 18-FDG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-05-20
    Completion
    2019-04-26
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCushing Syndrome; Endocrine Disease
    InterventionPentetreotide; 18F-DOPA; CT scan; MRI +1 more
    PhasePhase 2
    Registry statusCompleted

  • Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

    NCT00002967 · start 1997-05

    Registered record
    Registry ID
    NCT00002967
    Conditions
    Breast Cancer
    Interventions
    cyclophosphamide; doxorubicin hydrochloride; octreotide pamoate; tamoxifen citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1997-05
    Completion
    2006-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventioncyclophosphamide; doxorubicin hydrochloride; octreotide pamoate; tamoxifen citrate
    PhasePhase 3
    Registry statusCompleted

  • Cardiovascular Outcome After Surgery or Somatostatin Analogues

    NCT00615004 · start 1997-01

    Registered record
    Registry ID
    NCT00615004
    Conditions
    Acromegaly
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1997-01
    Completion
    2007-12
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcromegaly
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    NCT00227773

    Registered record
    Registry ID
    NCT00227773
    Conditions
    Gastrointestinal Carcinoid Tumor; Islet Cell Carcinoma
    Interventions
    octreotide acetate; vatalanib; anti-cytokine therapy; antiangiogenesis therapy; biological therapy; endocrine therapy; enzyme inhibitor therapy; growth factor antagonist therapy; hormone therapy; protein tyrosine kinase inhibitor therapy; somatostatin analogue therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Carcinoid Tumor; Islet Cell Carcinoma
    Interventionoctreotide acetate; vatalanib; anti-cytokine therapy; antiangiogenesis therapy +7 more
    PhasePhase 2
    Registry statusWithdrawn